These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 22362073)
1. Highlights in prostate cancer from the 2011 American Urological Association Annual Meeting and the 2011 American Society of Clinical Oncology Annual Meeting. Yu EY Clin Adv Hematol Oncol; 2011 Aug; 9(8 Suppl 21):1-24. PubMed ID: 22362073 [No Abstract] [Full Text] [Related]
2. Highlights in advanced prostate cancer from the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium. Clin Adv Hematol Oncol; 2013 Apr; 11(4 Suppl 7):1-22. PubMed ID: 23880604 [No Abstract] [Full Text] [Related]
3. Highlights in advanced prostate cancer from the 2012 American Urological Association Annual Meeting and the 2012 American Society of Clinical Oncology Annual Meeting. Shore ND Clin Adv Hematol Oncol; 2012 Aug; 10(8 Suppl 12):1-24. PubMed ID: 23072827 [No Abstract] [Full Text] [Related]
4. Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting. Miyahira AK; Sharp A; Ellis L; Jones J; Kaochar S; Larman HB; Quigley DA; Ye H; Simons JW; Pienta KJ; Soule HR Prostate; 2020 Feb; 80(2):113-132. PubMed ID: 31825540 [TBL] [Abstract][Full Text] [Related]
5. Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting. Miyahira AK; Cheng HH; Abida W; Ellis L; Harshman LC; Spratt DE; Simons JW; Pienta KJ; Soule HR Prostate; 2017 Nov; 77(15):1478-1488. PubMed ID: 28925066 [TBL] [Abstract][Full Text] [Related]
6. Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting. Miyahira AK; Den RB; Carlo MI; de Leeuw R; Hope TA; Karzai F; McKay RR; Salami SS; Simons JW; Pienta KJ; Soule HR Prostate; 2019 Feb; 79(3):244-258. PubMed ID: 30381857 [TBL] [Abstract][Full Text] [Related]
7. Current management of advanced and castration resistant prostate cancer. Gomella LG; Petrylak DP; Shayegan B Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717 [TBL] [Abstract][Full Text] [Related]
8. Caveolin-1 as a biomarker to predict therapeutic effect of low-frequency ultrasound combined with SonoVue on prostate cancer in nude mice model. Xu W; Nan S; Bai W; Shen E; Hu B Cancer Biomark; 2014; 14(4):279-86. PubMed ID: 24934371 [TBL] [Abstract][Full Text] [Related]
13. [Prostate cancer: the essential from the congress of the American Urological Association (AUA) 2005]. Descazeaud A Ann Urol (Paris); 2005 Oct; 39 Suppl 4():S89-101. PubMed ID: 16370172 [TBL] [Abstract][Full Text] [Related]
14. Progress in the treatment of advanced prostate cancer. Sternberg CN; Petrylak DP; Madan RA; Parker C Am Soc Clin Oncol Educ Book; 2014; ():117-31. PubMed ID: 24857068 [TBL] [Abstract][Full Text] [Related]
15. Highlights from the 5th Annual International Congress on Monoclonal Antibodies in Cancer Quebec City, Canada, August 2005; 5th International Prostate Cancer Congress, Rio Grande, Puerto Rico, July 2005; 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 2005. Clin Prostate Cancer; 2005 Sep; 4(2):73-8. PubMed ID: 16197605 [No Abstract] [Full Text] [Related]
16. Highlights of abstracts on hormone-refractory prostate cancer presented at the 1996 annual meeting of the American Society of Clinical Oncology. Roth BJ Semin Oncol; 1996 Dec; 23(6 Suppl 14):6-7. PubMed ID: 8996577 [TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer. Armstrong AJ Clin Adv Hematol Oncol; 2017 Mar; 15(3):184-188. PubMed ID: 28398272 [No Abstract] [Full Text] [Related]
18. Highlights in prostate cancer from the 2020 American Society of Clinical Oncology Annual Meeting. Clin Adv Hematol Oncol; 2020 Sep; 18(9):520-521. PubMed ID: 33006580 [No Abstract] [Full Text] [Related]
19. Do calcium channel blockers appear to have a protective effect on the development of prostate cancer clinically? Zhang P; Hu WL; Wang XH Urol Oncol; 2016 May; 34(5):242-3. PubMed ID: 27036219 [No Abstract] [Full Text] [Related]
20. Metalloproteinase 11, potential marker and molecular target in advanced and castration-resistant prostate cancer. Culture study of peritumoral fibroblasts. Fernandez-Gomez JM; Eiro N; García-Rodríguez JJ; Quintás-Blanco A; Gonzalez-Ruiz de León C; Perez de Haro ML; Vizoso-Piñero F Actas Urol Esp; 2017; 41(6):376-382. PubMed ID: 28161070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]